Eli Lilly & Co. (LLY) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardianc...
Eli Lilly & Co.'s revenue increased 44.7% year over year, from $45.04B to $65.18B.
Net income increased 94.9% over the same period, from $10.59B to $20.64B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 207% in total.
Total debt increased by 26.3% to $42.50B.
The debt-to-equity ratio stands at 1.60, indicating a elevated leverage profile.
Operating cash flow grew 90.7% to $16.81B.
Eli Lilly & Co. maintains a strong net profit margin of 31.7%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $24.77B+62.2% | $3.05B | $19.48B | $4.05B | $4.55B | $57.92B | $20.17B | $11.22B |
| Q1 FY2024 | $8.77B-64.6% | $2.24B | $7.09B | $2.54B | $1.17B | $63.94B | $26.21B | $12.81B |
| Q2 FY2024 | $20.07B+128.9% | $5.21B | $16.23B | $6.05B | $2.63B | $71.87B | $28.89B | $13.56B |
| Q3 FY2024 | $31.51B+57.0% | $6.18B | $25.50B | $7.64B | $6.34B | $75.61B | $31.12B | $14.24B |
| Q1 FY2025 | $12.73B-59.6% | $2.76B | $10.50B | $3.46B | $1.67B | $89.39B | $38.52B | $15.76B |
| Q2 FY2025 | $28.29B+122.2% | $8.42B | $23.61B | $10.23B | $4.75B | $100.92B | $39.90B | $18.27B |
| Q3 FY2025 | $45.89B+62.2% | $14.00B | $38.21B | $17.46B | $13.59B | $114.94B | $42.51B | $23.79B |
| Q1 FY2026 | $19.80B-56.9% | $7.40B | $16.22B | $8.85B | $5.33B | $116.58B | $43.37B | $31.20B |
Balance Sheet Summary (Latest Period)
Total Assets
$112.48B
Total Liabilities
$85.94B
Total Equity
$26.54B
Cash & Equivalents
$7.27B
Total Debt
$42.50B
Current Assets
$55.63B
Current Liabilities
$35.23B
Retained Earnings
$24.47B